1cP-LSD

The notice designates 1cP-LSD by its statutory chemical name and common name and sets its effective date and general prohibitions.

Sweden classifies 1cP-LSD as a narcotic in Bilaga 1 to Förordning (1992:1554) om kontroll av narkotika. Unauthorized sale, manufacture, acquisition for sale, possession, use, and other handling of narcotics are criminal offences under Narkotikastrafflag (1968:64); the basic offence carries imprisonment for up to three years.

Decision No. 2307 records the Gazette issue/date, Article 19 basis and annex entry for 1 cp-LSD. Turkey's official Narkotik Suçlarla Mücadele Başkanlığı page (dated 8 August 2024) describes the Early Warning System (EWS) route for newly appearing or high-risk NPS and says the generic-classification system brings many synthetic-drug derivatives under Law No. 2313. The official 2025 Türkiye Uyuşturucu Raporu explains that NPS are substances not controlled under the UN drug conventions, describes Turkey's EWS referral into Law No. 2313, and reports that from 2008–2024, 1,078 substances were included under relevant Law No. 2313 provisions, 453 directly through generic classification. The current Ministry of Justice TCK text provides conduct-specific penalties: Article 188(1) sets 20–30 years' imprisonment and 2,000–20,000 days' judicial fine for unlicensed manufacture, import or export; Article 188(3) sets at least 10 years and 1,000–20,000 days for unlicensed domestic sale, offering, giving, dispatch, transport, storage, purchase, acceptance or possession; Article 188(6) applies the preceding rules to substances producing narcotic or stimulant effects whose production requires official permission or sale requires an authorized prescription. Article 191(1) sets 2–5 years for purchase, acceptance, possession for use or use, while paragraphs (2)–(3) provide five-year prosecution postponement and probation/treatment rules. These are statutory conduct-specific ranges, not a claim that every case receives the same charge or sentence.

Covered by the Psychoactive Substances Act 2016,²⁷ effective May 26, 2016.²⁸ Subject to section 11 exceptions, sections 4, 5, 7, and 8 make intentional production, supply or offering to supply, possession with intent to supply, and import or export criminal offences when the applicable knowledge and psychoactive-consumption elements are met. Section 9, also subject to those exceptions, creates a possession offence in a custodial institution where the person knows or suspects the substance is psychoactive and intends to consume it for its psychoactive effects.

The current Anlage 1 Nr. 5.2 covers derivatives of the Δ9,10-ergolene core. Its R1 definition expressly permits a three- to seven-membered ring structure coupled through a carbonyl group whose carbonyl is bonded to the ergolene nitrogen; the N-cyclopropionyl designation therefore falls within that definition. A substance in an Anlage 1 group is a new psychoactive substance under § 2 Nr. 1 Buchstabe a. For that category, § 3 Abs. 1 Nr. 1 prohibits trafficking, placing on the market, manufacture, movement into, out of, or through the Act’s territorial scope, acquisition, possession, and administration to another. The relevant exceptions are the recognized commercial, industrial, or scientific uses in § 3 Abs. 2 Nr. 1 and official-authority/instructed-investigation uses in § 3 Abs. 2 Nr. 2; § 3 Abs. 2 Nr. 3 applies only to the separate § 3 Abs. 1 Nr. 2–4 cases.

The CDSA defines an analogue as a substance having a substantially similar chemical structure to a controlled substance, but the definition does not itself identify which unlisted substances are controlled; Health Canada explains that schedule listings may broaden scope when they expressly use terms such as salts, derivatives or analogues and provides a status-confirmation process for substances not explicitly listed. Schedule III item 5 uses only 'LSD ... and any salt thereof', unlike other schedule entries that expressly add derivatives or analogues. No substance-specific Health Canada status confirmation or Canadian court ruling classifies 1cP-LSD under a broader analogue rule. If a competent authority or court were to determine that 1cP-LSD is captured by a schedule heading, CDSA section 4(1) prohibits unauthorized possession of a Schedule III substance and section 4(6) provides up to three years by indictment, or summary-conviction fines up to $1,000/$2,000 and imprisonment up to six months/one year for first/subsequent offences. For a Schedule III substance, section 5(1) prohibits trafficking or possession for trafficking and section 5(3) provides up to 10 years by indictment or 18 months on summary conviction; section 6(1) prohibits unauthorized import/export and section 6(3) provides the same Schedule III penalty; section 7(1) prohibits production and section 7(2) provides the same penalty. Those penalties are conditional and conduct-specific; analytical grouping with LSD analogues alone does not establish that they apply to 1cP-LSD. Provincial rules, product formulation, customs facts and any authorization are outside the scope of the federal schedule.

The relevant e-Sbírka texts are the versions current on 28 August 2026, rather than the 2013 enactment alone. The current schedule does list LSD and 1p-LSD, which are distinct from 1cP-LSD; NIH PubChem identifies the latter's cyclopropanecarbonyl identity. The Czech NPS regime separately regulates substances only when they are placed on the classified-psychoactive list; the current classified-psychoactive list does not include 1cP-LSD. The Criminal Code provisions described here apply to substances that are legally omamné or psychotropní, not to unscheduled 1cP-LSD itself.